Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥65 years
Authors' conclusion
The findings suggest that RZV is not significantly associated with an increased risk of incident gout in the Medicare population aged ≥65 years.
Study context
- Population
- US fee-for-service Medicare (Part A, B, and D) beneficiaries aged ≥65 years receiving at least one dose of recombinant zoster vaccine (RZV) in 2018 or 2019RZV-exposed with incident gout
- Participants
- 1,290 participants
- Comparison
- Risk window vs control window after RZV
- Outcome
- Incident gout (first episode, no gout in the last 365 days)
Methodological detailscase-only, conditional Poisson regression
- Case-only
- Conditional Poisson regression
Main finding
As reported in the abstract
Incident gout, risk window (days 1-30) vs control window (days 31-60) after RZV
RR of incident gout
1.00 (0.90, 1.12) (95% CI)
Further findings
Incident gout, dose-compliant sensitivity analysis (dose 2 60-183 days after dose 1)
- RR of incident gout
- 0.99 (0.87, 1.13) (95% CI)
- n = 959 cases of incident gout
Incident gout, dose-specific, seasonality and COVID-19 sensitivity analyses
- Findings unchanged
Original publication
Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥65 years. Semin Arthritis Rheum. Published 15 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →